Investor Determination to Beat Cancer Puts NeOnc’s Novel Therapies and Patented Platform in Focus
NeOnc’s (NASDAQ:NTHI) CEO purchased another 37,000 shares of the company’s common stock, following a $15 financing with healthcare-focused institutions
NeOnc’s (NASDAQ:NTHI) CEO purchased another 37,000 shares of the company’s common stock, following a $15 financing with healthcare-focused institutions